DESCRIPTION

Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.

Virology is open to reviews, research manuscripts, short communication as well as follow-up manuscripts.

For more information on article types, please visit our guide for authors: https://www.elsevier.com/journals/virology/0042-6822/guide-for-authors

Virology offers guaranteed peer review of Follow-Up as well as Research Articles, provided the Corresponding Author is the same and the new manuscript is submitted within 12 months of the previous paper getting accepted.

ABSTRACTING AND INDEXING

Scopus
BIOSIS Citation Index
Biological Abstracts
Chemical Abstracts
Current Contents - Life Sciences and Clinical Medicine
Embase
Genetics Abstracts
Immunology Abstracts
PubMed/Medline
Research Alert
Science Citation Index
Tropical Diseases Bulletin
Virology and AIDS abstracts
Embase
EDITORIAL BOARD

**Lead Editor**
Jasmine Tomar, Elsevier B.V., 1043 NX, Amsterdam, Netherlands

**Editors**

Alexander Gorbalenya, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, Netherlands
- Virus Evolution, RNA Viruses, Comparative Genomics, Virus Taxonomy

David Knipe, Harvard Medical School, Department of Microbiology and Immunobiology, 200 Longwood Avenue, 02115-5701, Boston, Massachusetts, United States of America
- DNA viruses, Epigenetic of DNA virus infection, Herpesviral lytic and latent infection, Innate immunity and viruses, Viral Vaccines

Xue-Ping Zhou, Chinese Academy of Agricultural Sciences Institute of Plant Protection, 100193, Beijing, China
- Geminivirus, plant virus interaction, RNA silencing, detection

**Editorial board**

Walter Atwood, Brown University, Department of Molecular Biology, Cell Biology, and Biochemistry, Providence, Rhode Island, United States of America
- HIV, Hematopoietic stem cell, Gene therapy, Humanized mouse, RNA interference, CRISPR

Udeni Balasuriya, Louisiana State University School of Veterinary Medicine, Baton Rouge, Louisiana, United States of America
- Molecular virology, parthenogenesis, viral persistence

Lawrence M. Banks, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
- HPV, Viral Oncoproteins, Viral Entry, Cell Polarity, PDZ Domains

David Beasley, The University of Texas Medical Branch at Galveston, 77555, Galveston Texas, United States of America
- Flaviviruses, arboviruses, vaccines, pathogenesis, escape mutants

Graham J. Belsham, University of Copenhagen, Department of Veterinary and Animal Sciences, Frederiksberg, Denmark
- Picornaviruses, positive strand RNA viruses, viral protein synthesis, virus assembly, RNA replication, Molecular virology

Kate Bishop, The Francis Crick Institute, London, United Kingdom
- Retroviruses, HIV, MLV

Carol Blair, Colorado State University, Fort Collins, Colorado, United States of America
- Arthropod-borne viruses, vector biology, RNA interference

Michael Bouchard, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
- Hepatitis B virus, hepatitis, liver cancer, animal models of liver disease, fatty liver disease

Margo Brinton, Georgia State University, Department of Biology, Atlanta, Georgia, United States of America
- Immune response, T cells, chronic virus, LCMV, interferon

David Brooks, AIDS Institute, Dept. of Microbiology, Immunology and Molecular Genetics, UCLA Health System, Los Angeles, California, United States of America
- Alphavirus, virus entry, virus assembly

Roberto Cattaneo, Mayo Clinic in Rochester, Rochester, Minnesota, United States of America
- Cell entry, cell-cell transmission, respiratory viruses, quasi species

Wen Chang, Institute of Molecular Biology Academia Sinica, Taipei, Taiwan
- Poxvirus biology, virus entry, innate immune response, viral protein structure, membrane fusion, vaccinia virus, virus receptor

Linda Chelico, University of Saskatchewan College of Medicine, Saskatoon, Saskatchewan, Canada
- HIV, APOBEC, mutagenesis, biochemistry, enzyme-nucleic acid interactions

Zigui Chen, The Chinese University of Hong Kong, Department of Microbiology, Hong Kong, Hong Kong
- Virology, Bioinformatics, Molecular evolution, Genomics, Cancer

Donald Coen, Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Boston, Massachusetts, United States of America
- Include herpesviruses, DNA replication, gene expression, viral latency, and nuclear egress,

Jeffrey Cohen, National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases, Bethesda, Maryland, United States of America
- Vaccines, Epstein-Barr virus, herpes simplex virus

Andrés Carlos Alberto Culasso, University of Buenos Aires, Faculty of Pharmacy and Biochemistry, Buenos Aires, Argentina
- HCV, Virus Evolution, Phylogeny, Coalescence, bioinformatics

Rosa DEL ANGEL, Center for Research and Advanced Studies of the National Polytechnic Institute, Department of Genetics and Molecular Biology, Ciudad de México, Mexico
- Arbovirus, dengue, zika, replication, antiviral
Marlene Dreux, INSERM Regional Delegation Rhône-Alpes, Bron, France
virus, interferon, dendritic cells, innate immunity, COVID-19, immunology, virology, Dengue Virus

Blossom Damania, The University of North Carolina at Chapel Hill, Department of Microbiology and Immunology, Chapel Hill, North Carolina, United States of America
KSHV, herpesviruses, cancer biology

Neal DeLuca, University of Pittsburgh, Department of Microbiology and Molecular Genetics, Pittsburgh, Pennsylvania, United States of America
Herpesviruses, transcription, replication, molecular biology, pathogenesis

Felipe Diaz-Griffero, Michael F. Price Center, Dept. of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America
HIV-1, innate immunity, restriction factors, viral nuclear import, uncoating, MxB, TRIM5, SAMHD1

Shou-Wei Ding, University of California Riverside, Department of Microbiology and Plant Pathology, Riverside, California, United States of America
RNAi, viral suppressor of RNAi, RNA virus, plant virus, innate immunity

Dirk Dittmer, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
herpesviruses, Kaposi Sarcoma, sequencing, cancer

Esteban Domingo, Autonomous University of Madrid Severo Ochoa Molecular Biology Centre, Madrid, Spain
RNA viruses; evolution; quasispecies; antiviral resistance; HCV, FMDV; Sars-CoV-2

Jaquelin Dudley, The University of Texas at Austin, Department of Molecular Biosciences, Austin, Texas, United States of America
RNA viruses, paramyxovirus, pneumovirus, viral entry, viral replication, negative strand virus, viral spread

Matthew Evans, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
Bentley Fane, The University of Arizona, Tucson, Arizona, United States of America
bacteriophage, virus assembly, DNA packaging

Rachel Fearns, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America
Non-segmented negative strand RNA virus, RNA dependent RNA polymerase, transcription, genome replication

Matthias Fischer, Max-Planck-Institute for Medical Research, Department of Biomolecular Mechanisms, Heidelberg, Germany

Ervin Fodor, Sir William Dunn School of Pathology, Oxford, United Kingdom
Influenza, polymerase, transcription, replication

Paul Friesen, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
Molecular virology, DNA damage response, apoptosis, baculovirus

Gabrielle Fuchs, University at Albany, Department of Biological Sciences, Albany, New York, United States of America
translational regulation, internal ribosomal entry site, RNA viruses, ribosome heterogeneity/modifications

Michael Gale (Jr.), University of Washington, Department of Immunology, Seattle, Washington, United States of America
RNA viruses, innate immunity, interferon, cytokine, pathogenesis

Thomas Gallagher, Loyola University Chicago Microbiology and Immunology Department, Maywood, Illinois, United States of America
Microbiology, Virology, Cell Biology

Denise Galloway, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America
Virology, Cancer viruses, human papillomavirus, Merkel Cell polyomavirus

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, New York, United States of America
Influenza, RNA viruses, Antivirals, vaccines, Virus-host interactions

Benjamin Gewurz, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
Epstein-Barr virus pathogenesis, gamma-herpesvirus, lymphogenesis, metabolism, CRISPR/Cas9, viral oncogenes

Wade Gibson, Johns Hopkins University, Department of Pharmacology and Molecular Sciences, Baltimore, Maryland, United States of America
Herpesvirus, proteins, assembly, protease

Heinrich Gottlinger, University of Massachusetts Medical School Program in Gene Function and Expression, Worcester, Massachusetts, United States of America
HIV-1, Retroviruses, Virus-Host interactions, Nef, SERINC5

Eva Gottwein, Northwestern University, Department of Microbiology-Immunology, Chicago, Illinois, United States of America
Oncogenic viruses, miRNA, Kaposi's Sarcoma associated herpesvirus, CRISPR-based functional genomics.

Charles Grose, Howard Hughes Medical Institute - University of Iowa, Iowa City, Iowa, United States of America
herpes virus, varicella-zoster virus, autophagy, herpes virus assembly, pathogenesis

Rahm Gummuluru, Boston University, Department of Microbiology, Boston, Massachusetts, United States of America
HIV, Innate Immunity, Cell-to-cell transmission, Virus Entry, Nanotechnology

Kurt Gustin, The University of Arizona College of Medicine Phoenix, Phoenix, Arizona, United States of America
RNA Viruses, Picornaviruses, Innate Immunity, stress granules, nucleo-cytoplasmic trafficking

Mark Heise, The University of North Carolina at Chapel Hill Division of Infectious Diseases, Chapel Hill, North Carolina, United States of America
Arboviruses, SARS-CoV-2, Pathogenesis, Innate Immunity, Host Genetics

Ekaterina (Katya) Heldwein, Tufts University School of Medicine, Boston, Massachusetts, United States of America
herpesviruses, viral entry, viral egress, glycoproteins, structural biology, biochemistry, biophysics

Tom Hobman, University of Alberta, Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
Reovirus, Innate Immunity, Interferon, Interferon Stimulated Genes, Viral oncolytics

Brenda Hogue
Coronaviruses, RNA viruses, virus assembly, virus replication

Geoffrey Holm, Colgate University, Hamilton, New York, United States of America
Reovirus, Innate Immunity, Interferon, Interferon Stimulated Genes, Viral oncolytics

Curt M. Horvath, Northwestern University, Evanston, Illinois, United States of America
Interferon, paramyxovirus, innate immunity, antivirals, gene expression

Yao-Wei Huang, South China Agricultural University College of Veterinary Medicine, Guangzhou, China
Virus, coronavirus, PRRSV, hepatitis E virus, vaccine, immune response, emerging animal diseases

Eric Jan, The University of British Columbia, Department of Biochemistry and Molecular Biology, Vancouver, British Columbia, Canada
RNA virus, translation, ribosome, protease, innate immune response

James Jancovich, California State University San Marcos, Department of Biological Sciences, San Marcos, California, United States of America
Ranavirus, pathogenesis, host-pathogen interactions, genomics

Karyn Johnson, The University of Queensland School of Biological Sciences, Saint Lucia, Australia
insect viruses, Wolbachia, arboviruses, miRNA

Clare Jolly

Catherine Jopling, University of Nottingham, Nottingham, United Kingdom
microRNA, hepatitis C virus

Yoshihiro Kawaoka, University of Wisconsin at Madison, School of Veterinary Medicine; Influenza Research Inst., Dept. of Pathobiological Sciences, Madison, Wisconsin, United States of America
influenza, ebola, COVID-19, SARS-CoV-2, Pathogenesis

Shannon Kenney
epstein-barr virus, mononucleosis, lymphoproliferative disease, DNA tumor virus, humanized mouse

Aloysius Klingelhoetz, The University of Iowa, Iowa City, Iowa, United States of America
Adipose, Ebola, HPV, Inflammation, Skin, Metabolic Syndrome, PCBs

Thomas Kristie, National Institutes of Health, Bethesda, Maryland, United States of America
herpes simplex virus, DNA virus gene expression

Mart Krupovic, Pasteur Institute, Department of Microbiology, Paris, France
archaeal viruses, ssDNA viruses, origin of viruses, virus evolution

Mark Krystal, ViV Healthcare US, Research Triangle Park, North Carolina, United States of America
HIV, influenza virus, RSV, antivirals, virus entry

Jens Kuhn, Integrated Research Facility, Frederick, Maryland, United States of America
arenaviruses, bunyaviruses, filoviruses, BSL-4, virus taxonomy

Michael Lagunoff, University of Washington, Department of Microbiology, Seattle, Washington, United States of America
KSHV, oncogenic viruses, herpesviruses, viral metabolism, cancer, HHV-8

Laimonis A. Laimins, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
HPV, DNA damage, gene expression, differentiation

Mansun Law
Viral hepatitis, HCV, antibody, B cell

Benhur Lee, Icahn School of Medicine at Mount Sinai, Department of Microbiology, New York, New York, United States of America
Virus Entry, Fusion, Emerging Viruses, Reverse Genetics, Paramyxovirus, Virus Budding, Antivirals,
Neutralizing antibodies, negative sense RNA virus, Gene editing, Viral delivery systems

Elliot Lefkowitz, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America
Genomics, Bioinformatics, Evolution, Poxviruses, Taxonomy, Virology

Petr Leiman, The University of Texas Medical Branch at Galveston, Department of Biochemistry and Molecular Biology, Galveston, Texas, United States of America
Bacteriophage structure and function, Bacteriophage host recognition, Viral receptor-binding proteins, X-ray crystallography, Cryo-electron microscopy, Phage-derived RNA polymerases, Type VI Secretion System

Fangfang Li, Chinese Academy of Agricultural Sciences Institute of Plant Protection, Beijing, China
Plant virology, RNA regulation, Gene expression, Protein degradation

Wenhui Li, National Institute of Biological Sciences Beijing, Beijing, China
hepatitis B virus, coronavirus, viral entry, antivirals, episome

Zhenghe Li, Zhejiang University College of Agriculture and Biotechnology, Hangzhou, China
plant negative-stranded RNA viruses, plant rhabdoviruses, plant bunyaviruses, plant viral vector, plant genetic engineering, agricultural biotechnology

Richard Lloyd, Baylor College of Medicine, Houston, Texas, United States of America
Reovirus, RNA virus, stress granule, poxvirus, processing body (P-body), poliovirus, translation control, plus-stranded RNA virus, eukaryotic initiation factor 2 (eIF2), eukaryotic translation initiation, double-stranded RNA (dsRNA), translation, virus

Volker Lohmann, Molecular Virology, Dept. of Infectious Diseases, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
Hepatitis C virus, Positive strand RNA viruses, Norovirus, replication organalle, Innate immune response

Guangxiang George Luo

Jason Mackenzie, The University of Melbourne, Melbourne, Australia
Flavivirus, Norovirus, innate immunity, metabolism, Lipids, imaging, Virology

Bernardo A. Mainou, National Center for Immunization and Respiratory Diseases Division of Viral Diseases, Atlanta, Georgia, United States of America
Virus entry, virus and host interactions, oncolytics, reoviruses, picornaviruses, Virus-Microbial Interactions

Shinji Makino, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America
Coronavirus, Rift Valley fever virus and molecular virology, Virology

Encarnacion Martinez-Salas

Andrew Meule, University of Wisconsin Madison, Department of Medical Microbiology and Immunology, Madison, Wisconsin, United States of America
influenza virus, RNA-dependent RNA polymerase, virus, host range restriction, host interactions

Xiang-Jin Meng, College of Veterinary Medicine, Department of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute & State University, Blacksburg, Virginia, United States of America
Positive-strand RNA viruses, small DNA viruses, vaccine, emerging viruses, zoonotic viruses, pathogenesis, innate immunity, viral replication

Edward Mocarski, Emory University, Atlanta, Georgia, United States of America
Viral DNA, viral replication, viral immunology, immunology, virus assembly, herpesvirus, viral protein, virus structure, viral polymerase, viral protease, virus entry, DNA viruses, viral transcription, animal virus, virus

Thomas E. "Tem" Morrison, University of Colorado Anschutz Medical Campus, Department of Immunology & Microbiology, Aurora, Colorado, United States of America
Arbovirus, Immune response, Pathogenesis

Martin Muggeridge, Louisiana State University Health Sciences Center, Department of Microbiology and Immunology, Shreveport, Louisiana, United States of America
virus entry, glycoprotein, membrane fusion

Tuli Mukhopadhyay, Indiana University Bloomington, Bloomington, Indiana, United States of America
Virus assembly, RNA viruses

Karl Munger, Tufts University School of Medicine, Department of Developmental, Molecular and Chemical Biology, Boston, Massachusetts, United States of America
Viral oncology, oncogenes, tumor suppressors, papillomaviruses

Carsten Munk, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
HIV, retroviruses, restriction factors, innate immunity

Nedzad Music, Seqirus, A CSL Company, Research and Science, Cambridge, Massachusetts, United States of America
RNA virus, replication, recombination, host-virus interaction, plant virus

Max L. Nibert, Harvard Medical School, Boston, Massachusetts, United States of America
RNA viruses, Virus assembly, Virus-cell interactions, Virus entry, Virus evolution, Virus structure

David Ornelles, Wake Forest University, Department of Microbiology and Immunology, Winston-Salem, North Carolina, United States of America
Nikolaus (Klaus) Osterrieder, City University of Hong Kong, Jockey Club College of Veterinary Medicine and Life Sciences, Department of Infectious Disease and Public Health, Hong Kong, Hong Kong
Herpesvirus, Coronavirus, Vaccine, Pathogenesis

Jing-Hsiung Ou, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America
Virology, hepatitis B virus; hepatitis C virus; hepatocellular carcinoma

Cara Pager

Colin R. Parrish, Cornell University, College of Veterinary Medicine, Department of Microbiology and Immunology, Ithaca, New York, United States of America
Virology, parvovirus, influenza virus, virus structure, virus evolution

Andrew Pekosz, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America
Influenza, respiratory epithelial cells, coronavirus, virus assembly, enterovirus D-68

Stanley Perlman, The University of Iowa, Department of Microbiology and Immunology, Iowa City, Iowa, United States of America
coronavirus, respiratory syndrome, neurovirology

Ted Pierson

James Pipas, University of Pittsburgh, Department of Biological Sciences, Pittsburgh, Pennsylvania, United States of America
Polyomaviruses, Innate immunity, Tumor viruses, Metagenomics, Viral Emergence

Massimo Pizzato, University of Trento, Trento, Italy
HIV, innate immunity, virology

Dohun Pyeon, Michigan State University, Department of Microbiology and Molecular Genetics, East Lansing, Michigan, United States of America
Tumor Virology, Cancer Immunology, HPV, Immune Evasion, Head and Neck Cancer

Feng Qu, Dept. of Agricultural, Environmental, and Development Economics, College of Food, Agricultural and Environmental Sciences, The Ohio State University, Columbus, Ohio, United States of America
Plant virus, virus evolution, replication, virus-host interaction

Glenn Rall, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America
Measles, Neuron, Interferon, Influenza, Astrocyte

ALN Rao, University of California Riverside, Department of Microbiology and Plant Pathology, Riverside, California, United States of America
Genome packaging, Capsid dynamics, Replication, Virus-Host Interactions, Virology

Venigalla Rao
Bacteriophage, Virus assembly, DNA packaging, Vaccine design, Gene Therapy

Rolf Renne, University of Florida, Department of Molecular Genetics & Microbiology, Gainesville, Florida, United States of America
g-herpesviruses, cancer biology, non-coding RNAs, microRNAs, epigenetics

Stephen Rice, University of Minnesota Twin Cities School of Medicine, Minneapolis, Minnesota, United States of America
herpesvirus, herpes simplex virus, immediate-early protein, gene regulation, ICP27, viral replication mechanisms

Erle Robertson, 203D Johnson Pavilion, Dept. of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

Ann Roman, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America

Raymond Roos
Picornavirus infections, Cardioviridae, central nervous system virus infections, unconventional virus infections, prion disease

Selena Sagan, McGill University, Department of Microbiology & Immunology, Montréal, Quebec, Canada
Hepatitis c virus, microRNAs, Zika virus, Dengue virus, respiratory syncytial virus, Virology, RNA biology

Martin J. Sapp, Louisiana State University Health Sciences Center, Department of Microbiology and Immunology, Shreveport, Louisiana, United States of America
HPV, Viral attachment, Viral entry, Viral trafficking

Herman Scholthof, Intercollegiate Fac. of Virology, Dept. of Plant Pathology & Microbiology, Texas A&M University, College Station, Texas, United States of America
Plant virus movement, plant virus silencing, plant virus CRISPR

Bert Semler, University of California Irvine, Department of Microbiology & Molecular Genetics, Irvine, California, United States of America
Picornaviruses, positive-strand RNA viruses, RNA virus replication, virus-host interactions

Nathan Sherer, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America
retroviruses, viral transmission, viral gene expression, virus assembly, virus RNA trafficking, Virology, Cell Biology, Pharmacology, HIV, HPV, HBV, Antiviral Drugs
Zhengli Shi, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, China
coronavirus
Christina Sigurdson, University of California at San Diego Center for Veterinary Sciences and Comparative Medicine, La Jolla, California, United States of America
Neurodegenerative disease, prion disease, amyloid disorders, neuropathology
Mark Slifka, Oregon Health & Science University Oregon National Primate Research Center, Beaverton, Oregon, United States of America
immunology, virology, vaccines, immunological memory
Deborah Spector, University of Pittsburgh Molecular Biology, Pittsburgh, Pennsylvania, United States of America
Herpesvirus, Zika virus, molecular and cellular biology, vaccines
Klaus Strebel, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States of America
HIV, host restriction, accessory proteins, virus-host interactions
Bill Sugden, University of Wisconsin-Madison McArdle Laboratory for Cancer Research, Madison, Wisconsin, United States of America
Epstein-Barr Virus, Kaposi's Sarcoma Herpesvirus, Transformation, DNA Replication
Christopher S. Sullivan, The University of Texas at Austin, Austin, Texas, United States of America
Noncoding RNAs, RIG-1, polyomaviruses
Xiangjie Sun, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Influenza virus, pathogenesis, transmission, immunity, animal models of viral infection
Nobuhiro Suzuki, Okayama University Institute of Plant Science and Resources, Okayama, Japan
Fungal virus, Antiviral RNA silencing, Virocontrol, dsRNA virus, Neovirology
Chad Swanson
Innate immunity, RNA binding proteins, HIV, antiviral proteins, influenza virus
John Teijaro, The Scripps Research Institute, La Jolla, California, United States of America
Viral immunology, cytokines, immune suppression, respiratory viruses, chemical immunology
Juan C de la Torre, The Scripps Research Institute, La Jolla, California, United States of America
RNA Virus-host interactions, antiviral drugs, vaccines, viral hemorrhagic fevers
Ralph Tripp, University of Georgia, Department of Infectious Diseases, Athens, Georgia, United States of America
viral immunology, RNA viruses, therapeutics, vaccines, host-pathogenesis
Thijs Van De Laar, Sanquin Blood Supply Foundation, Amsterdam, Netherlands
Molecular Epidemiology, Hepatitis, HIV, STI, Molecular diagnostics
Koenraad Van Doorslaer, The University of Arizona School of Animal and Comparative Biomedical Sciences, Tucson, Arizona, United States of America
Evolution, cancer, small DNA tumor viruses, innate immunity
Scott Vande Pol, Clinical Microbiology, Health Sci.C,Dept. of Pathology, Virginia Commonwealth University, Charlottesville, Virginia, United States of America
Papillomavirus, E6, cervical cancer, tumor viruses
Nikos Vasilakis, The University of Texas Medical Branch at Galveston, Department of Pathology, Galveston, Texas, United States of America
Arbovirus, evolution, virus-vector-host interactions, flavivirus, alphavirus, insect specific viruses
Aiming Wang, London Research and Development Centre, London, Ontario, Canada
Plant Virology, Plant Genetics and Genomics, Plant Molecular Biology, Molecular Virus-Plant Interactions, Plant Immunity to Microbes
David Wang, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States of America
Virome, Orsay virus, astrovirus, enteric viruses, emerging viruses, polyomavirus, viral genomics and bioinformatics
Brian Ward, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
Poxviruses, DNA Viruses, Enveloped Viruses, Morphogenesis, Viral interaction with the cytoskeleton.
Richard Webby, Dept. of Infectious Diseases, Div. of Virology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America
Influenza, zoonoses
Elizabeth White, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America
Virology, human papillomavirus, epithelial cell biology, carcinogenesis, viral oncoproteins
K. Andrew White, York University, Department of Biology, Toronto, Ontario, Canada
RNA structure, RNA folding, RNA virus, plant virus, viral gene expression
Jason Whitmire, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
T cell responses, pathogenesis, mouse models, LCMV, HAV, Epigenetics, obesity, virus infections

**Michael Whitt**, The University of Tennessee Health Science Center, Memphis, Tennessee, United States of America

Virus entry, Membrane fusion, Negative-strand virus replication

**Michelle Wille**, The University of Sydney School of Life and Environmental Sciences, Camperdown, Australia

**Joyce Wilson**, University of Saskatchewan, Department of Microbiology and Immunology, Saskatoon, Saskatchewan, Canada

RNA structure, virus genome replication, virus-host interactions, host targeting therapeutics, reporter genomes and replicons

**Jian Ye**, Institute of Microbiology Chinese Academy of Sciences, Beijing, China

DNA viruses, geminivirus, arbovirus, innate immunity, virus transmission, tripartite interaction, Negative stranded RNA virus, Tospovirus

**Donwan Yoo**, University of Illinois Urbana-Champaign, Urbana, Illinois, United States of America

Arterivirus, PRRS, Veterinary virology, Innate immunity, Coronaviruses

**Allan Zajac**, The University of Alabama at Birmingham, Department of Microbiology, Birmingham, Alabama, United States of America

Immune response, immunopathology, T cell exhaustion, virus persistence, T cells

**Francisco Zerbini**, Federal University of Viçosa, Department of Plant Pathology, VICOSA, Brazil

plant viruses, geminivirus, begomovirus, molecular evolution

**Yong-Zhen Zhang**, Shanghai Public Health Clinical Center, Shanghai, China

Virus diuversity, Evolution and ecology, Infectious Disease

**Michael Zwick**, Scripps Research Institute Immunology and Microbiology, La Jolla, California, United States of America

viral entry mechanism, broadly neutralizing antibodies, vaccine design, host immunity, human infectious disease, virus envelope glycoprotein structure-function

**Editorial Advisory Board**

**Ahmed Abdel-Moneim**, Taif University, Taif, Saudi Arabia

Virus diagnosis, Virus host interaction, Virus evolution, Viruses and public health

**Helle Bielefeldt-Ohmann**, University of Queensland, Brisbane, Queensland, Australia

Virus pathogenesis, Virus-host cell interactions, Arboviruses, Respiratory viruses, Vaccines

**Shengbo Cao**, Huazhong Agricultural University, Wuhan, China

Japanese encephalitis virus, Flavivirus, Pathogenesis, Vector-borne infectious diseases,

**WeiChuan Fang**, Zhejiang A&F University, Hangzhou, China

Porcine viruses, Pathogenesis, Host antiviral responses, Immune evasion, Vaccinology

**Matteo Iannacone**, Vita-Salute San Raffaele University, Milano, Italy

Adaptive immunity, Liver, Imaging, HBV, LCMV, VSV, SARS-CoV-2

**Dong-Yan Jin**, The University of Hong Kong School of Biomedical Sciences, Hong Kong, Hong Kong

Viral oncogenesis, Innate antiviral response, Virus-host interaction, Inflammasome, vaccines

**Anil Kumar**, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Arbovirology, Virus-host interactions, Genetic screens, Innate immunity, Positive strand RNA viruses

**Rik de Swart**, Wageningen Bioveterinary Research, Lelystad, Netherlands

Measles, Morbillivirus, Respiratory syncytial virus, Pathogenesis, Correlates of protection

**Xianbing Wang**, China Agricultural University, Beijing, China

Insect-borne plant viruses, Antiviral RNA silencing, Negative-stranded RNA viruses, Virus-plant-insect interactions

**Fei Yan**, Ningbo University, Ningbo, China

Plant virus, Rice virus, Plant immunity, Host-virus interaction

**Chunfu Zheng**, University of Calgary, Department of Microbiology Immunology and Infectious Diseases, Calgary, Alberta, Canada

Herpesviruses, Virus-host interaction, Antiviral innate immunity, Viral immune evasion, Emerging viruses, signaling pathways, cGAS-STING, TLR, RIG-I, RLR
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

INTRODUCTION

Virology publishes papers that provide advances to the understanding of virus biology. We have been publishing the results of basic research in all branches of virology for over 60 years. The journal welcomes submitted articles on virus replication, virus-host biology, viral pathogenesis, immunity to viruses, virus structure, and virus evolution and ecology. Articles should be of broad interest to the community of virologists. We also publish state-of-the-art invited reviews from experts in the field.

Types of paper

Virology publishes three forms of manuscripts: (a) research manuscripts (b) brief communications consisting of short but complete studies (c) reviews; and (d) Follow up manuscripts.

Research manuscripts present the results of original basic research in all areas of virology described above that break new ground and serve as a valuable addition to the literature in the field.

Brief Communications are short self-contained studies of significant and timely findings. Brief communications should have a maximum of 4 presentation items (combination of figures and tables). The organization of a Brief Communication is the same as that of a Regular manuscript. It is expected that the review of a Brief Communication will take into account the nature of its more limited scope. Manuscripts describing viral sequences without a significant advance in virus biology are not appropriate as Brief Communications.

Reviews describe cutting-edge developments and themes of interest to virologists. The goal of a review is to focus on a sharply defined topic and to make the information accessible to researchers who work in other areas of virology. Reviews should not cover the field in question comprehensively but rather address fundamental concepts, recent findings, and important unresolved issues. We welcome submission of proposals for reviews. All review submissions should be pre-approved by invitation either by an editor or by sending a pre-submission inquiry to the Editor-in-chief or another editor of Virology with a proposed review outline.

Follow up manuscripts are the continuation of published research manuscripts in the same journal. They capture new research findings that support the previously published data (same journal) and further advance the field by providing new scientific insights. These manuscripts will be linked to the original counterparts for better visibility and high impact. Papers will be published in Virology under one of the following subheadings:

- Virus Replication/Gene Expression
- Virus Structure and Assembly
- Virus-Cell Biology
- Gene Therapy/Viral Vectors
- Emerging Viruses
- Unconventional Agents
- Viral Pathogenesis
- Immunity
- Technological Advances
- Genomes and Evolution

Authors should understand that space limitations make it impossible to publish manuscripts that describe work that does not break new ground conceptually, particularly if the work merely mirrors work done on a closely related virus without adding significant new knowledge, such as partial
sequences of related viruses, evolutionary studies based on partial sequences, or descriptions of antigenic relationships and epitopes. Exceptions will be made, however, if these data reveal new insights into the fundamental properties of the virus.

**Contact details for submission**
The editors and their areas of responsibility are given here. For any pre-submission inquiry, please send an email to Virologyedoffice@elsevier.com along with the title and abstract of the manuscript.

**Peer Review Process:** Each editor is responsible for having manuscripts reviewed and for making the final decision concerning the disposition. Each manuscript is reviewed by at least two reviewers. All manuscripts are reviewed as rapidly as possible, and an editorial decision is usually reached within 4 to 5 weeks of the manuscript's submission.

**Submission checklist**
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

**Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files (where applicable)*

*Supplemental files (where applicable)*

Further considerations
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

**BEFORE YOU BEGIN**

*Additional Information*
Virology strongly encourages the correct usage and uniformity of virus names as defined by the International Committee on Taxonomy of Viruses (ICTV). The ICTV rules of orthography should be consulted at the ICTV website https://talk.ictvonline.org/information/w/faq/386/how-to-write-virus-species-and-other-taxa-names

**Requirements for deposition of structural data**

For papers describing structures of biological macromolecules from electron microscopy experiments, the 3D map should be deposited at either the EMBL-EBI (UK) or RCSB (USA) EMDB deposition site (http://www.emdatabank.org/). Once the map has been deposited, any fitted atomic coordinates should be deposited with the Protein Data Bank (PDB) by following the link provided from the EMDB deposition session. The EMDB and PDB IDs should be included in the manuscript. Both the map and the coordinate data will be made public when the associated article is published.
Ethics in publishing
Please see our information on Ethics in publishing.

Policy and ethics
Publication of a research article in Virology is taken to imply that the authors are prepared to distribute freely to academic researchers for their own use any materials (e.g., viruses, cells, DNA clones, antibodies) used in the published experiments. Prior to publication, nucleotide sequences and protein sequences must be deposited with GenBank (Web site: http://www.ncbi.nlm.nih.gov/Genbank/) and an accession number obtained for publication in the manuscript. X-ray crystallographic coordinates must be deposited with the Protein Data Bank (Web site: http://www.rcsb.org/pdb/).

DUAL USE RESEARCH OF CONCERN. Authors and reviewers must notify the editor-in-chief if a manuscript reports potential dual use research of concern. The editor-in-chief will evaluate potential dual use research of concern papers and, if necessary, will consult additional reviewers.

Declaration of competing interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors should complete the declaration of competing interest statement using this template and upload to the submission system at the Attach/Upload Files step. Note: Please do not convert the .docx template to another file type. Author signatures are not required. If there are no interests to declare, please choose the first option in the template. More information.

Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier's AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

Disclosure instructions
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

Please note that online publication of a submitted article prior to acceptance (i.e. under revision) is also strictly forbidden without the written consent of the copyright holder.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that
its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify compliance, your article may be checked by Crossref Similarity Check and other originality or duplicate checking software.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Preprint posting on SSRN
In support of Open Science, this journal offers its authors a free preprint posting service. Preprints provide early registration and dissemination of your research, which facilitates early citations and collaboration.

During submission to Editorial Manager, you can choose to release your manuscript publicly as a preprint on the preprint server SSRN once it enters peer-review with the journal. Your choice will have no effect on the editorial process or outcome with the journal. Please note that the corresponding author is expected to seek approval from all co-authors before agreeing to release the manuscript publicly on SSRN.

You will be notified via email when your preprint is posted online and a Digital Object Identifier (DOI) is assigned. Your preprint will remain globally available free to read whether the journal accepts or rejects your manuscript.

For more information about posting to SSRN, please consult the SSRN Terms of Use and FAQs.

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Reporting sex- and gender-based analyses

Reporting guidance
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should integrate sex and gender-based analyses (SGBA) into their research design according to funder/sponsor requirements and best practices within a field. Authors should address the sex and/or gender dimensions of their research in their article. In cases where they cannot, they should discuss this as a limitation to their research's generalizability. Importantly, authors should explicitly state what definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility of their research and to avoid ambiguity or conflation of terms and the constructs to which they refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use and editorial review of sex and gender information in study design, data analysis, outcome reporting and research interpretation - however, please note there is no single, universally agreed-upon set of guidelines for defining sex and gender.

Definitions
Sex generally refers to a set of biological attributes that are associated with physical and physiological features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical and cultural context and may vary across societies and over time. Gender influences how people view themselves and each other, how they behave and interact and how power is distributed in society. Sex and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging whereas these constructs actually exist along a spectrum and include additional sex categorizations and gender identities such as people who are intersex/have differences of sex development (DSD) or identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important for authors to define the manner in which they are used. In addition to this definition guidance and the SAGER guidelines, the resources on this page offer further insight around sex and gender in research studies.

Author contributions
For transparency, we require corresponding authors to provide co-author contributions to the manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles describing each contributor’s specific contribution to the scholarly output. The roles are: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; and Writing - review & editing. Note that not all roles may apply to every manuscript, and authors may have contributed through multiple roles. More details and an example.

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.
For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

**Open access**
Please visit our Open Access page for more information.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Authors are required to submit the names and e-mail addresses of a minimum of four potential referees who are not current Editors of the journal.

**Additional information**

**Special Subject Repositories**
Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post certain articles such as those funded by the National Institutes of Health under its Public Access policy (see https://www.elsevier.com/about/open-science/open-access/agreements for more details on our policy and specific arrangements with various funding bodies, including NIH).

As an author you retain certain rights such as making copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use. See https://www.elsevier.com/copyright for an overview of all of these rights, as well as those of your employer or institution.

Language Polishing. Authors who require information about language editing and copyediting services pre- and post-submission please visit https://webshop.elsevier.com/language-editing/ or visit our Support Center for more information. Please note Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services or in any advertising. For more information please refer to our Terms & Conditions https://www.elsevier.com/legal/elsevier-website-terms-and-conditions.

**PREPARATION**

**Queries**
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.
NEW SUBMISSIONS
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

Streamline Reviews
If you have a manuscript that has been reviewed and rejected from a high impact journal (Impact Factor over 8 such as Nature, Science, PNAS, Cell Host Microbe, or PLOS Pathogens), you can send us the original reviews, your rebuttal, and a revised manuscript. You should include these extra items as part of your cover letter. We will consider the manuscript based on these reviews. We reserve the option of sending it for an additional assessment, in which case the additional reviewer(s) will also have access to your previous reviews. However, either way it will save you time as you don’t need to start the review process all over again with new reviews. This option works best for manuscripts rejected from a high impact journal for perceived reasons of impact, novelty, or significance.

References
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

Material and methods
Materials and methods should provide sufficient information to permit the work to be repeated and should be kept concise by referring to previously published procedures. With increasing studies on pathogenicity of viruses, it is important that the provenance of viruses be stated clearly.

Keywords
Immediately after the abstract, provide a maximum of 10 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abstract
Abstract must not exceed 150 words

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. For how to write virus, species, and other taxa names, you are urged to consult the International Committee on Taxonomy of Viruses (ICTV): https://talk.ictvonline.org/files/ictv_documents/m/gen_info/7004. The same ICTV web-site provides up-to-date virus taxonomy. Commonly used vernacular names may be used after viruses are first correctly identified. Genetic loci should be italicized; protein products of the loci are not italicized.

Please note that the instructions related to Graphical abstract still apply to all new submissions.

Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible
for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

REVISED SUBMISSIONS

Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Subdivision - unnumbered sections
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.
Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 x 1328 pixels (h x w) or proportionally more. The image should be readable at a size of 5 x 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Database linking
Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

For papers describing experimentally determined structures of biological macromolecules, the atomic coordinates and related experimental data (structure factor amplitudes/intensities and/or NMR restraints and chemical shifts) must be deposited in the PDB at a member site of the Worldwide Protein Data Bank (wwPDB.org). The wwPDB validation report for each structure should be provided upon manuscript submission.

For papers describing structures of biological macromolecules from electron microscopy experiments (all averaging methods, including sub-tomogram averaging), the 3D map should be deposited in EM Data Bank (EMDB: emdatabank.org). Any fitted atomic coordinates should be deposited with the Protein Data Bank (PDB). For electron tomographic studies with no averaging, deposition of one or more representative tomograms in EMDB is strongly recommended. The EMDB and PDB IDs should be included in the manuscript, together with a brief descriptive title for each accession. In cases where PDB models have been fitted into EMDB maps, the correspondences between them should be clearly stated. Both the map and the coordinate data must be made public when the associated article is published.

See https://www.elsevier.com/databaselinking for more information and a full list of supported databases.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available. You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. Further information on the preparation of electronic artwork.

Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.
Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Free Reference Style
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:


Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Research Elements**

This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in a Research Elements journal.

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a manuscript to one of the Research Elements journals.

More information can be found on the Research Elements page.

**Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**AFTER ACCEPTANCE**

**Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to
MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com